EP4506003A1 — Halogen derivatives of (4´,5´- methylenedioxyphenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline for use in the treatment of leukemia
Assigned to Republican Specialized Scientific Pratical Medical Center Of Hematology Of Ministry Of Public Health Of Republic Of Uzbekistan · Expires 2025-02-12 · 1y expired
What this patent protects
The use of compounds with the following structural formula is proposed:wherein R represents Br (compound F1) or Cl (compound F2),as agents that have cytotoxic activity against CCRF-CEM cells (T-lymphoblastic leukemia) and exhibit an antitumor effect against various types of leuke…
USPTO Abstract
The use of compounds with the following structural formula is proposed:wherein R represents Br (compound F1) or Cl (compound F2),as agents that have cytotoxic activity against CCRF-CEM cells (T-lymphoblastic leukemia) and exhibit an antitumor effect against various types of leukemia - T-acute lymphoblastic leukemia (T-ALL), B-acute lymphoblastic leukemia (B-ALL), acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), acute myelomonoblastic leukemia (AMML and acute monocytic leukemia (AML).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.